ILD during Erlotinib and Gefitinib Treatment in Japanese
Patients with Nonsmall Cell Lung Cancer
To the Editor:
Hotta et al. compared the incidence and pattern of interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer receiving treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Two different cohorts of patients were compared: unselected patients treated with gefitinib between 2000 and 2003 and selected patients with a lower proportion of known risk factors for ILD treated with erlotinib in 2008. 1 This article highlights the importance of appropriate patient selection to minimize the risk of ILD with EGFR TKIs: indeed, the authors concluded that patient selection, because of recent awareness of risk factors for ILD, may explain their numerical difference in ILD incidence between the two EGFR TKIs in these different time frames. We found the article interesting and were encouraged to note that the authors acknowledge numerous limitations in their comparison. We would also like to point out that Table 1 incorrectly stated that 8% of patients (rather than the correct 38% of patients) who were treated with gefitinib had a poor performance status, an independent risk factor for ILD, compared with 20% of those who were treated with erlotinib.
In 2002, AstraZeneca, the manufacturer of gefitinib, added ILD to the list of known adverse reactions in the prescribing information. 2 Subsequently, a large epidemiological study in Japanese patients with non-small cell lung cancer, designed and conducted by an independent academic team together with scientists from AstraZeneca, identified a number of risk factors for developing ILD (irrespective of whether the patient received gefitinib or chemotherapy). 3 AstraZeneca added these risk factors to the prescribing information 2 for gefitinib in 2006 to provide this important information to prescribers as a part of proactive risk mitigation. The prescribing information for gefitinib has since been refined and updated several times to enable clinicians and patients to make informed prescribing choices: the warning on this event expanded with risk factors for mortality associated with ILD, and frequency of ILD updated to 1.3% (based on the phase III clinical program). 2 This labeling has resulted in increased awareness and appropriate patient selection, which is reflected by the reduction in reporting rates of ILD with EGFR TKIs. For gefitinib, the reported incidence rate of ILD in Japan has reduced from 5.8% in 2003-2004 4 to the current incidence rate of 1.28% (0.64% in regions outside Japan) (AstraZeneca, data on file).
Stephanie-Jayne Jones, MRCP Tsveta Milenkova, MD AstraZeneca Alderley Park Macclesfield, Cheshire, United Kingdom 
In Response:
Thank you for the special attention on our article. Yes, in our article, we wanted to simply stress the importance of appropriate patient selection to minimize the risk of interstitial lung disease (ILD) with epidermal growth factor receptor tyrosine kinase inhibitor rather than the difference itself in the incidence of ILD with both agents. Indeed, one can also obtain the similar observation in a previous Japanese study. 1 This shows that the incidence of ILD has decreased over years in the gefitinib treatment for Japanese cohort with 3.0 and 1.4% in 2002 and 2008, respectively.
We sincerely apologize for the incorrect description of the proportion of poor performance status patients treated with gefitinib monotherapy, as Dr. Jones and colleagues suggested. We, medical oncologists, truly applaud the great efforts of AstraZeneca company and thank for the refined and updated proscribing information for gefitinib. Thanks to this, we can now properly make the appropriate patient selection and can obtain the excellent data showing the safety and effectiveness of gefitinib monotherapy in the first-line setting in the selected patient population. 2 Katsuyuki Hotta, MD, PhD Nagio Takigawa, MD, PhD Katsuyuki Kiura, MD, PhD
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